INCIDENCE AND MANAGEMENT OF CHEMOTHERAPY-INDUCED ADVERSE DRUG REACTIONS IN CANCER PATIENTS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i10.55479Keywords:
Chemotherapy,, Adverse drug reactions, Pharmacovigilance, Cancer, Anticancer drugsAbstract
Objectives: The objective of the study is to evaluate the prevalence, pattern, severity, causality, and preventability of chemotherapy-induced adverse drug reactions (ADRs) in cancer patients at a north Indian rural tertiary care teaching hospital.
Methods: One hundred cancer patients undergoing chemotherapy were recruited for this 12-month prospective observational study. Purposive sampling was employed, and data were gathered through patient interviews, interactions with healthcare professionals, and spontaneous ADR reporting. The Schumock and Thornton scale, the Modified Hartwig and Siegel scale, and Naranjo’s scale were used to evaluate the causation, severity, and preventability of ADRs.
Results: Among 100 patients, 58% were female and 48% were aged 41–60 years. A total of 271 ADRs were reported. Combination therapy accounted for 78% of ADRs, while 22% were linked to monotherapy. Gastrointestinal ADRs were the most frequent (38.75%), followed by skin-related and hematological reactions. Most ADRs were classified as mild (84.87%), possible in causality (67.15%), and not preventable (64.94%). Despite ADRs, 77% of patients continued chemotherapy.
Conclusion: Chemotherapy-induced ADRs are common and predominantly associated with combination regimens. Strengthening pharmacovigilance and implementing individualized treatment strategies may help to mitigate and address ADR burden, thereby improving patient outcomes.
Downloads
References
1. Lafargue P, Rogerson M, Parry GC, Allainguillaume J. Broken chocolate: Biomarkers as a method for delivering cocoa supply chain visibility. Supply Chain Manag Int J. 2022 Nov 23;27(6):728-41. doi: 10.1108/scm-11-2020-0583
2. Yuan TA. Reactive Oxygen Species Associated Risk and Gender- Specific Risk Disparities of Cutaneous Melanoma. California: University of California Irvine; 2020.
3. Waks AG, Winer EP. Breast cancer treatment: A review. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323, PMID 30667505
4. Anand U, Dey A, Chandel AK, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023 Jul 1;10(4):1367-401. doi: 10.1016/j.gendis.2022.02.007, PMID 37397557
5. Nagumo WR. Pharmacovigilance and Adverse Drug Reaction Reporting Practices among Ghanaian Healthcare Professionals [Doctoral Dissertation, University of Sheffield].
6. Pandian JD, Kalkonde Y, Sebastian IA, Felix C, Urimubenshi G, Bosch J. Stroke systems of care in low-income and middle-income countries: Challenges and opportunities. Lancet. 2020 Oct 31;396(10260):1443-51. doi: 10.1016/S0140-6736(20)31374-X, PMID 33129395
7. Danbatta A, Musa A, Adeyemi O. Pattern of adverse drug reactions of anticancer drugs in oncology unit of A tertiary care teaching hospital in South West, Nigeria. Afr J Pharm Res Dev. 2016;8(2):100-7.
8. Sharma A, Gupta V, Sood S, Kaushal V. Age distribution and cancer incidence in a tertiary care center: A retrospective study. J Cancer Res Ther. 2019;15(4):890-4.
9. Globocan. Global Cancer Statistics. International Agency for Research on Cancer (International Arctic Research Center); 2020. Available from: https://gco.iarc.fr
10. Furqan M, Dachriyanus D, Susanti M, Putra PP, Wahyuni FS. Unravelling the interaction between garcinisidone-A and HER2 protein in breast cancer: A computational study. Int J Appl Pharm. 2024;16(Suppl 1): 99-104.
11. Mohan A, Sarin A, Malhotra P, Kumar R, Mohanti BK. Prevalence of oral cancers in India: A clinical study of trends and risk factors. Asian Pac J Cancer Prev. 2021;22(3):655-62.
12. Reddy CR, Rao BN, Kumar DS, Sharma A, Patel S, Mehta S. Distribution of various cancers in a regional cancer center. J Oncol Sci. 2018;4(1):45-51.
13. Verma R, Gupta P, Garg R, Bhushan R. Adverse drug reactions in cancer patients receiving chemotherapy: A cohort study. J Cancer Res Ther. 2017;13(6):1011-5.
14. Mukherjee S, Bhattacharya D, Ghosh S, Ghosh AK. Adverse drug reactions associated with chemotherapy: A study from an oncology unit in India. Indian J Pharmacol. 2016;48(6):635-41.
15. Fatmi SM, Dhar K, Sharma J, Dutta S. Assessment and management pattern of chemotherapeutic drug induced adverse effects among cancer patients at tertiary Care Centre. J Pharm Res Int. 2022;33(60B):605-14. doi: 10.9734/jpri/2021/v33i60b34659
16. Deng S. VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple- Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy. Tennessee: The University of Tennessee Health Sciences Center; 2020.
17. Singh N, Kumar S, Sharma R, Patel S, Goyal N, Gupta P. Gastrointestinal toxicities in cancer patients undergoing chemotherapy: A prospective study. J Gastrointest Oncol. 2019;10(4):578-86.
18. Patel S, Amin J, Jani H. Skin toxicities related to taxane-based chemotherapy regimens in cancer patients: A clinical evaluation. Dermatol Ther. 2020;33(5):e13754.
19. Permatasari D, Aini N, Yosmar R. Effects of post-chemotherapy drugs on the liver function tests in pediatric patients with acute lymphoblastic leukemia (ALL). Int J Appl Pharm. 2025;17(Suppl 1):61-6. doi: 10.22159/ijap.2025.v17s1.09
20. Kumar M, Singh H, Goyal N, Sharma R, Patel S, Mehta D, et al. Hematological toxicities in patients undergoing chemotherapy for various malignancies: A retrospective study. Indian J Hematol Blood Transfus. 2018;34(2):214-9.
21. Malik P, Dutta R, Chauhan D, Sharma A, Verma R, Gupta N, et al. Causality assessment of adverse drug reactions in oncology: An observational study using Naranjo’s scale. J Clin Oncol Pharmacol. 2017;9(3):243-9.
22. Patel BJ, Patel CR. Assessment of causality, severity and preventability of adverse drug reactions of cancer chemotherapy in a tertiary care teaching hospital, Gujarat, India. Int J Pharm Sci Res. 2021;12(7): 3950-58.
23. Koliyakodu PS, Sudhakar R, Kurian MM. A prospective observational study on evaluation of chemotherapy induced adverse drug reactions in cancer patients in a tertiary Care Hospital. Indian J Pharm Pract. 2021;14(1):27-31.
Published
How to Cite
Issue
Section
Copyright (c) 2025 AMRESH KUMAR, ALOK DIXIT, CHANDRA VEER SINGH, POOJA SINGH, KAILASH MITTAL, AJIT KUMAR MISHRA
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
